创新药板块深度回调，创新药沪深港ETF（517110）跌近3%，或可把握低位布局机会

Group 1 - The innovative drug sector is experiencing a significant pullback, with the Shanghai-Hong Kong-Macau ETF (517110) declining nearly 3%, presenting potential low-position investment opportunities [1] - The pharmaceutical and biotechnology industry shows notable differentiation: chemical pharmaceuticals are performing well, with a projected revenue growth rate of 4.2% year-on-year in 2024 and a substantial net profit growth of 97.7%, driven by rapid market penetration of innovative drug products and reduced losses [1] - The CRO/CMO sector is recovering, with revenue expected to show quarter-on-quarter improvement in 2024, and a growth rate of 11.2% in Q1 2025, significantly surpassing the industry average decline of 4.3% [1] Group 2 - The overall pharmaceutical sector is impacted by high base effects and weak consumer demand, but there are prominent structural opportunities driven by innovation [1] - Current valuations in the pharmaceutical sector are at historical lows, highlighting attractive cost-performance ratios for investment [1] - The Shanghai-Hong Kong-Macau ETF (517110) tracks the SHS Innovative Drug (RMB) Index (931409), which includes 50 listed companies involved in innovative drug research and production, reflecting the overall performance of the innovative drug sector [1]